ADVR to Present at the 2005 Annual Assembly of the AAHPM and HPNA
WEDNESDAY, DECEMBER 01, 2004 07:00 AM
YONKERS, N.Y., Dec 1, 2004 (BUSINESS WIRE) --ADVR will Report Results on its Phase I/II Clinical Trial of
AVR118 in Patients with AIDS
Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today
announced that James T. D'Olimpio, M.D., has been invited to give an
oral presentation at the 2005 Annual Assembly of the American Academy
of Hospice and Palliative Medicine (AAHPM) and Hospice and Palliative
Nurses Association (HPNA) to be held January 19-23, 2005, in New
Orleans, LA.
Dr. D'Olimpio will deliver an oral presentation entitled,
"Efficacious Reversal of AIDS Related Anorexia/Cachexia Syndrome:
Final Results of a Phase I/II Study Using a Novel Peptide-Nucleic Acid
Complex." The presentation is scheduled for 10:00 a.m. on January 22,
2005.
The presentation will report final results on the Phase I/II
clinical trial of AVR118 in patients with AIDS. The 30-patient trial
was conducted at the Kaplan Medical Center in Israel in cachetic AIDS
patients.
"We are delighted that our abstract has been selected to be given
as an oral presentation at such a prestigious conference," said Dr.
Elma Hawkins, President and CEO of Advanced Viral Research Corp. "The
joint meeting of the AAHPM and HPNA is the premier meeting of
palliative medicine and all presentations given at the conference are
selected based on peer review."
The American Academy of Hospice and Palliative Medicine (AAHPM) is
the only organization in the United States for physicians dedicated to
the advancement of hospice/palliative medicine, its practice, research
and education. AAHPM members are physicians and other healthcare
professionals from many medical specialties who are committed to
furthering and fostering the practice of hospice/palliative care for
the terminally ill and their families.
ADVR's AVR118 is a biopolymer that possesses novel immunomodulator
activity. This peptide-nucleic acid complex, which, to date, has
demonstrated a very favorable safety profile, appears to stimulate the
pro-inflammatory responses required to combat viral infections such as
HIV and human papillomavirus and to dampen aberrant autoimmune-type
inflammatory responses, such as occur in patients with rheumatoid
arthritis. Data presented at the American Society of Clinical
Oncology's (ASCO) annual meeting in June, 2004, showed that AVR118
appears to have activity against fatigue, loss of appetite, and weight
loss in patients with HIV.
For further information regarding Advanced Viral Research Corp.,
please visit our website at www.adviral.com. ADVR, based in Yonkers,
New York, is a biopharmaceutical firm dedicated to improving patients'
lives by researching, developing and bringing to market new and
effective therapies for viral and other diseases.
Note: This news release contains forward-looking statements that
involve risks associated with clinical development, regulatory
approvals, including application to the FDA, product commercialization
and other risks described from time to time in the SEC reports filed
by the Company. AVR118 (Product R) is not approved by the U.S. Food
and Drug Administration or any comparable agencies of any other
countries. There is no assurance that the Company will be able to
secure the financing necessary to continue and/or complete the
clinical trials of AVR118 or satisfy certain other conditions relating
to clinical trials including obtaining adequate insurance on terms
acceptable to the Company or that if completed, clinical trials
performed outside the United States will assist the Company in
obtaining FDA or other regulatory approval. The Company undertakes no
obligation to update or revise the information contained in this
announcement whether as a result of new information, future events or
circumstances or otherwise.
SOURCE: Advanced Viral Research Corp.
CWR & Partners
cobrand.knobias.com |
